Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing

Immunology

Volumn 141, Issue 2, 2014, Pages 242-255

  Siena, Liboria ^a   Pace, Elisabetta ^a   Ferraro, Maria ^a   Di Sano, Caterina ^a   Melis, Mario ^a   Profita, Mirella ^a   Spatafora, Mario ^b   Gjomarkaj, Mark ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apoptosis; Cytotoxic lymphocytes; Fas ligand; Gemcitabine; Non small cell lung cancer

Indexed keywords

CASPASE 3; CASPASE 8; FAS ANTIGEN; FAS LIGAND; GEMCITABINE; MESSENGER RNA; NEUTRALIZING ANTIBODY; PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL KILLING; COLORIMETRY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; FLOW CYTOMETRY; LUNG CANCER; LYMPHOKINE ACTIVATED KILLER CELL; PLEURA FLUID; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CYTOTOXIC LYMPHOCYTES; FAS LIGAND; GEMCITABINE; NON-SMALL CELL LUNG CANCER;

ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DEOXYCYTIDINE; FAS LIGAND PROTEIN; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS;

EID: 84891894205     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12190     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Gridelli C, Maione P, Rossi A, Ferrara ML, Castaldo V, Palazzolo G, Mazzeo N. Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer 2009; 66:282-6.
3. Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer 2010; 70:340-6.
4. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110-7.
5. Pace E, Melis M, Siena L, Bucchieri F, Vignola AM, Profita M, Gjomarkaj M, Bonsignore G. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines. Cancer Chemother Pharmacol 2000; 46:467-76.
6. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30:180-92.
7. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407:789-95.
8. Fulda S, Los M, Friesen C, Debatin KM. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 1998; 76:105-14.
9. Müller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403-13.
10. Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R, Tesoriere G. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007; 12:1327-38.
11. Hour MJ, Yang JS, Chen TL et al. The synthesized novel fluorinated compound (LJJ-10) induces death receptor-and mitochondria-dependent apoptotic cell death in the human osteogenic sarcoma U-2 OS cells. Eur J Med Chem 2011; 46:2709-21.
12. Son K, Fujioka S, Iida T, Furukawa K, Fujita T, Yamada H, Chiao PJ, Yanaga K. Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells. Anticancer Res 2009; 29:3995-4003.
13. Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 1997; 180:70-83.
14. + NKT cell-mediated cytotoxicity. Int J Cancer 2006; 119:1630-7.
15. Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells. J Immunother 2005; 28:332-42.
16. Wei J, De Angulo G, Sun W et al. Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother 2009; 58:259-70.
17. Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol 2012; 188:4441-9.
18. Ling C, Xie Y, Zhao D, Zhu Y, Xiang J, Yang J. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther 2012; 19:697-706.
19. Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 2010; 23:189-96.
20. Cozens AL, Yezzi MJ, Yamaya M et al. A transformed human epithelial cell line that retains tight junctions post crisis. In Vitro Cell Dev Biol 1992; 28A:735-44.
21. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-8.
22. Carbone A, Rodeck U, Mauri FA et al. Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol Ther 2005; 4:231-41.
23. Pace E, Di Sano C, Ferraro M et al. Altered CD94/NKG2A and perforin expression reduce the cytotoxic activity in malignant pleural effusions. Eur J Cancer 2011; 47:296-304.
24. Mattis AE, Bernhardt G, Lipp M, Förster R. Analyzing cytotoxic T lymphocyte activity: a simple and reliable flow cytometry-based assay. J Immunol Methods 1997; 204:135-42.
25. Pace E, Siena L, Ferraro M et al. Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis. Eur J Cancer 2006; 42:2382-9.
26. Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug. Expert Opin Investig Drugs 2001; 10:1075-84.
27. Schulte M, Reiss K, Lettau M et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ 2007; 14:1040-9.
28. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003; 193:70-81.
29. O'Reilly LA, Tai L, Lee L et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461:659-63.
30. Maginn EN, Browne PV, Hayden P et al. PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. Br J Cancer 2011; 104:281-9.
31. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000; 60:7133-41.
32. Laussmann MA, Passante E, Düssmann H et al. Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8. Cell Death Differ 2011; 18:1584-97.
33. Holler N, Zaru R, Micheau O et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1:489-95.
34. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005; 116:458-63.
35. - cells and display an impaired capability to kill tumor cells. Cancer 2008; 112:863-75.
36. Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol 2003; 22:431-7.